Results 41 to 50 of about 8,893 (235)

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study

Cardiovascular Diabetology, 2021
Aim We aimed to compare cardiovascular outcomes of patients with type 2 diabetes (T2D) who initiated GLP-1 receptor agonists (GLP-1RA) or basal insulin (BI) under routine care.
Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini   +5 more
doaj   +1 more source

Incretin-based therapy for the treatment of bone fragility in diabetes mellitus [PDF]

, 2018
Bone fractures are common comorbidities of type 2 diabetes mellitus (T2DM). Bone fracture incidence seems to develop due to increased risk of falls, poor bone quality and/or anti-diabetic medications.
B. Bouvard, B. Gobron, D. Chappard, G. Mabilleau   +3 more
core   +2 more sources

Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists

Pharmaceuticals, 2022
Glucagon-like peptide-1 (GLP-1) is easily degraded by dipeptidyl peptidase-4 (DPP-4) in the human body, limiting its therapeutic effect on type II diabetes.
Lei Sun, Zhi-Ming Zheng, Chang-Sheng Shao, Zhi-Yong Zhang, Ming-Wei Li, Li Wang, Han Wang, Gen-Hai Zhao, Peng Wang   +8 more
doaj   +1 more source

Canagliflozin: A Review in Type 2 Diabetes. [PDF]

, 2017
peer reviewedCanagliflozin (Invokana(R)) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated in various countries worldwide for the once-daily oral treatment of type 2 diabetes (T2D).
Deeks, Emma D., Scheen, André
core   +2 more sources

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain [PDF]

, 2016
Objective: Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment.
Aguilera, Eva, Ampudia Blasco, Francisco Javier, Anglada, Jordi, Arguelles, Iñaqui, Bellido Guerrero, Diego, Brito Sanfiel, Miguel Ángel, Casanueva, Felipe, Conget, Ignacio, Cuatrecasas, Guillem, De Castro Hernández, Paloma, De la Cuesta, Carmen, De Teresa Parreño, Luis, Detournay, Bruno, Escalada, Francisco Javier, Fernández Catalina, Pablo, Garcia Puig, Juan, García, Honorato, Gaztambide, Sonia, Giménez, Margarita, Gómez Peralta, Fernando, Gómez, Luis Alberto, Hernández Herrero, Cristina, Hernández Mijares, Antonio, Mangas Cruz, Miguel Ángel, Manzanares, Jose María, Martínez, Encarna, Masmiquel, Lluís, Mauricio, Dídac, Merino Torres, Juan Francisco, Miralles García, José Manuel, Muros, Teresa, Ortega, Rafael, Pérez Maraver, Manuel, Soto González, Alfonso, Tréscoli, Carlos, Vinagre, Irene   +35 more
core   +4 more sources

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy

Journal of Diabetes Investigation, 2023
Aims/Introduction Previous studies have reported that the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) delays gastric emptying, and gastric emptying was assessed by the 13C breath test or paracetamol absorption technique.
Toshiko Kobori, Yukiko Onishi, Yoko Yoshida, Tazu Tahara, Takako Kikuchi, Tetsuya Kubota, Masahiko Iwamoto, Tomonobu Sawada, Reo Kobayashi, Hiroaki Fujiwara, Masato Kasuga   +10 more
doaj   +1 more source

Long-acting GLP-1RAs

JAAPA, 2020
ABSTRACT Over recent decades, an improved understanding of the pathophysiology of type 2 diabetes mellitus (T2DM) and glucose regulation has led to innovative research and new treatment paradigms. The discovery of the gut peptide glucagon-like peptide-1 (GLP-1) and its role in glucose regulation paved the way for the class of GLP-1 receptor ...
Ji Hyun, Chun, Amy, Butts
openaire   +4 more sources

Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs:The CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors) [PDF]

, 2017
Background: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus ...
Arya, Niki, Birkeland, Kåre I., Bodegård, Johan, Cavender, Matthew A., Fenici, Peter, Fu, Alex Z., Hammar, Niklas, Holl, Reinhard W., Jørgensen, Marit Eika, Khunti, Kamlesh, Kosiborod, Mikhail, Norhammar, Anna, Thuresson, Marcus, Wilding, John P.   +13 more
core   +2 more sources

Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)

, 2023
Purpose: To investigate trends in SGLT2i and GLP-1RA use in Australia in the era of increased evidence of their cardiovascular benefits. Methods: We used national dispensing claims for a 10% random sample of Australians to estimate the number of ...
Brieger, D, Day, RO , de Oliveira Costa, J , Falster, MO , Greenfield, JR , Havard, A , Lin, J , Park, KH, Pearson, SA   +8 more
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source